| |
Financial Year 2007 - 2008
Quarter IV
(March 2008)
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE PERIOD ENDED
30TH SEPTEMBER 2007
| (Rs.in Million ) |
| Sl. No |
Particulars |
Quarter ended 30th September |
Half Year ended 30th September |
Year ended
31st March 2007
(Audited) |
| 2007 (Un Audited) |
2006 (Un Audited) |
2007 (Un Audited) |
2006 (Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15.
16.
17.
|
Net Sales/Income from Operations
- Sales (net)
- Other Income for Operation
- Income from Potential patent infringment suit
total
Other Income
Total Income(1+2)
Expenditure
a) (Increase) / Decrease in Stock trade and
work in progress
b) Materials Consumed
c) Purchase of traded goods
d) Employee.cost
e)Depreciation
& Amortization
f)Other Expenditure
Total Expenditure
Profit before R&D& Interest(3-4)
Research and Development Expenditure
Interest
Profit from Ordinary Activities before Tax(5-6-7)
Tax expense(net)
Profit /(Loss) after Tax before Minority Interest and share in
Less : Minority Interest
Less : Share of loss in associate
Net Profit/ (Loss) (11-12-13)
Equity Capital
Reserves excluding revaluation reserves
E.P.S (Not annualised)
- Basic
- Diluted
Aggregate of Public Shareholding
-Number of shares - Face value of Rs.2 / - each
-Percentage of Shareholding
|
3764.10
22.02
67.66
3853.78
43.10
3896.88
(392.27)
1682.63
649.00
410.23
149.29
796.06
3294.94
601.94
347.50
235.08
19.36
125.27
(105.91)
12.13
(5.47)
(99.25)
308.99
-
(0.64)
(0.64)
36,782,911
23.81%
|
3731.78
26.38
67.66
3825.82
34.59
3860.41
(719.33)
1,711.36
1,025.44
473.00
128.30
672.24
3291.01
569.40
226.26
194.54
148.60
(6.16)
154.76
5.01
(1.18)
158.59
307.96
-
1.03
1.01
69,100,420
44.88%
|
8,234.26
31.90
134.57
8400.73
138.46
8539.19
32.74
2,829.77
1,541.40
866.50
298.63
1,511.83
7080.87
1458.32
639.54
443.09
375.69
232.78
142.91
32.15
(5.47)
169.59
308.99
-
1.10
1.10
36,782,911
23.81%
|
8,153.38
29.37
134.57
8317.32
104.22
8421.54
(262.87)
2,699.78
2,159.30
928.17
265.60
1.347.39
7137.37
1284.17
403.28
351.45
529.44
19.00
510.44
(10.15)
(3.68)
496.61
307.96
-
3.23
3.16
69,100,420
44.88%
|
16,480.27
44.16
268.39
16792.82
231.79
17024.61
(250.84)
5,332.35
3,898.76
1,773.35
540.70
2,997.12
14291.44
2733.17
1,007.56
704.19
1,021.42
264.89
756.53
6.57
0.00
763.10
308.24
-
4.96
4.93
36,405,635
23.62%
|
Segment Information
Segment Revenue:
-Pharmaceuticals
-Medical Supplies
Less: Inter segment Revenue
Net Segment Revenue
Segment Results :
Profit before tax and interest from each segment
-Pharmaceuticals
-Medical Supplies
Total
Less: Interest
Other unallocable
Income/(Expenditure)
Total Profit before tax
Capital Employed :
-Pharmaceuticals
-Medical Supplies
-Unallowable
Total Capital Employed :
|
3,424.30
339.80
-
3764.10
248.93
5.51
254.44
(235.08)
-
19.36
13,239.53
378.17
11714.66
25332.36
|
3,206.33
525.45
-
3731.78
335.71
7.43
343.14
(194.54)
-
148.60
13133.68
259.95
11466.73
24860.36
|
7,501.12
733.14
-
8,234.26
791.10
27.68
818.78
(443.09)
-
375.69
13,239.53
378.17
11,714.66
25,332.36
|
7,012.70
1,140.68
-
8,153.38
840.68
40.21
880.89
(351.45)
-
529.44
13,133.68
259.95
11,466.73
24,860.36
|
14,283.02
2,197.25
-
16,480.27
1,627.41
98.20
1,725.61
(704.19)
-
1,021.42
15,403.30
188.21
11,920.21
27,511.72
|
|
| Notes : |
The above results were reviewed by the Audit Committee, considered and approved by the Board of Directors at thier meeting held on 30st October 2007.
The above results include the financials of Subsidiaries - Matrix Laboratories BV, Matrix Laboratories NV, Docpharma NV & its subsidiaries, Matrix Singapore Pte Ltd. - The Company became a subsidiary of MP Laboratories (Mauritius) Limited, with effect from 8th January 2007. The ultimate holding company is Mylan Laboratories Inc, USA.
- The figures for the previous year / period have been rearranged wherever necessary to conform to current period's presentation.
Matrix Laboratories Limited , through its wholly owned subsidiary, has executed Definitive Agreements to acquire the residual holding of Mr. Mark Gao , the erstwhile promoter of Mchem group of Companies of China. Matrix had earlier acquired 60% equity in Mchem Group as a part of its backward integration strategy to secure the supply chain for intermediates. This acquisition would be subject to various approvals that are required to be obtained.
|
| |
For and on behalf of the Board
|
Place : Mumbai
Date : 30th October 2007 |
Rajiv Malik
Managing Director & Chief Executive Officer
|
|
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
30th SEPTEMBER 2007
| (Rs.in Million ) |
| Sl. No |
Particulars |
Quarter ended 30th September |
Half year ended 30th september |
Year ended
31st March 2007
(Audited) |
| 2007 (Un Audited) |
2006 (Un Audited) |
2007 (Un Audited) |
2006 (Un Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
| Net Sales/Income from Operation
-Exports
-Domestic
-Other Income from Operations
-Income from Potential patent infringement suit
Total
Other Income
Total Income(1+2)
Expenditure
a) (Increase) / Decrease in Stock in trade and work in progress
b) Materials Consumed
c) Purchase of traded goods
d)Employee cost
e)Depreciation & Amortization
f) Other Expenditure
Total Expenditure
Profit before R&D,Interest(3-4)
Research and Development Expenditure
Interest
Profit from Ordinary Activities before tax(5-6-7)
Tax expenses(net)
Net Profit for the period(8-9)
Paid-up equity share Capital(Face value - Rs.2/- each)
Reserves excluding revaluation reserves
Earning Per Share(E.P.S)(Not annualised)
- Basic
- Diluted
Public Shareholding
-Number of shares
-Percentage of Shareholding
|
1179.84
840.72
44.03
67.66
2132.25
41.44
2173.69
(173.45)
1206.28
0.85
159.48
71.37
388.84
1653.37
520.32
241.28
55.92
223.12
86.72
136.40
308.99
-
0.88
0.88
36,782,911
23.81%
|
839.17
583.56
52.76
67.66
1543.15
21.24
1564.39
(109.65)
878.98
2.16
131.16
62.76
289.92
1255.33
309.06
163.33
34.94
110.79
14.70
96.09
307.96
-
0.62
0.61
69,100,420
44.88%
|
2524.75
1556.82
63.79
134.57
4279.93
116.11
4396.04
(132.19)
2216.79
1.29
344.69
145.90
729.26
3305.74
1090.30
451.17
103.59
535.54
141.22
394.32
308.99
-
2.56
2.54
36,782,911
23.81%
|
2008.47
1365.99
58.74
134.57
3567.77
91.45
3659.22
329.79
1573.37
4.88
286.85
120.82
550.59
2866.30
792.92
303.75
66.66
422.51
36.70
385.81
307.96
-
2.51
2.45
69,100,420
44.88%
|
5051.77
2440.44
88.33
268.39
7848.93
162.08
8011.01
(28.22)
3789.51
99.03
598.38
250.71
1271.52
5980.93
2030.08
800.92
154.01
1075.15
79.02
996.13
308.24
9388.77
6.48
6.43
36,405,635
23.62%
|
|
| Notes : |
- The above results were subjected to a limited review by the Auditors, reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 30th October 2007.
- The figures for the previous year / period have been rearranged wherever necessary to conform to current period's presentation.
- The activities of the Company relate to only one business segment i.e. Pharmaceuticals.
- During the Quarter 51,206 Equity Shares of Rs. 2 each at a premium of Rs.169 and 45,300 Equity Shares of Rs 2 each at a premium of Rs 142.63 were allotted, on exercise of stock options under the Employees Stock Option Scheme.
- Matrix Laboratories Limited , through its wholly owned subsidiary, has executed Definitive Agreements to acquire the residual holding of Mr. Mark Gao , the erstwhile promoter of Mchem group of Companies of China. Matrix had earlier acquired 60% equity in Mchem Group as a part of its backward integration strategy to secure the supply chain for intermediates. This acquisition would be subject to various approvals that are required to be obtained.
- Summary of Investor Complaints
Opening : 1 , Received during the quarter : Nil , Resolved : 1 , Closing : Nil
- Provision for tax includes Current tax Rs 23.03 Millions (Quarter year ended 30th September 2006 Rs 5 Millions), Deferred tax Rs 63.53 Millions (Quarter ended 30th September 2006 Rs 12.5 Millions) and Fringe benefit tax Rs 7 Million (Quarter ended 30th September 2006 Rs 2.2 Millions) and is net of MAT credit available of Rs 6.84 Millions (Quarter ended 30th September 2006 Rs 5 Millions).
|
| |
For and on behalf of the Board
|
Place : Mumbai
Date : 30th October 2007 |
Rajiv Malik
Managing Director & Chief Executive Officer
|
|
|
